Proteases—From Basic Structure to Function to Drug Design as Targeted Therapy
In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibit...
Zapisane w:
| Format: | Online |
|---|---|
| Język: | angielski |
| Wydane: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Hasła przedmiotowe: | |
| Dostęp online: | ONIX_20220111_9783036525754_928 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|
| _version_ | 1869527223900307456 |
|---|---|
| collection | Directory of Open Access Books |
| description | In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Bartošová-Sojková et al. 2021). |
| format | Online |
| id | doab-20.500.12854ir-77096 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-770962024-03-27T16:34:42Z Proteases—From Basic Structure to Function to Drug Design as Targeted Therapy Kwok, Hang Fai Shaw, Christopher Walker, Brian MMP MMP2 MMP9 MMP7 MMP14 matrix metalloproteases PDAC pancreatic cancer Bowman–Birk inhibitor ranacyclin trypsin inhibitor structure–activity relationship synergistic effect Gentamicin matrix metalloproteinase extracellular matrix nuclei cancer apoptosis immune response cysteine protease inhibitor stefin signal peptide parasite phylogenetic analysis diversification protein structure vascular endothelial growth factors (VEGFs) VEGF-A PlGF VEGF-B VEGF-C VEGF-D angiogenesis lymphangiogenesis CCBE1 proteases ADAMTS3 plasmin cathepsin D KLK3 prostate-specific antigen (PSA) thrombin wound healing metastasis proteolytic activation vascular biology lymphedema thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Bartošová-Sojková et al. 2021). 2022-01-11T13:52:02Z 2022-01-11T13:52:02Z 2021 book ONIX_20220111_9783036525754_928 9783036525754 9783036525747 https://directory.doabooks.org/handle/20.500.12854/77096 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4715 https://mdpi.com/books/pdfview/book/4715 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2574-7 10.3390/books978-3-0365-2574-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036525754 9783036525747 93 Basel, Switzerland open access |
| spellingShingle | MMP MMP2 MMP9 MMP7 MMP14 matrix metalloproteases PDAC pancreatic cancer Bowman–Birk inhibitor ranacyclin trypsin inhibitor structure–activity relationship synergistic effect Gentamicin matrix metalloproteinase extracellular matrix nuclei cancer apoptosis immune response cysteine protease inhibitor stefin signal peptide parasite phylogenetic analysis diversification protein structure vascular endothelial growth factors (VEGFs) VEGF-A PlGF VEGF-B VEGF-C VEGF-D angiogenesis lymphangiogenesis CCBE1 proteases ADAMTS3 plasmin cathepsin D KLK3 prostate-specific antigen (PSA) thrombin wound healing metastasis proteolytic activation vascular biology lymphedema thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general Proteases—From Basic Structure to Function to Drug Design as Targeted Therapy |
| title | Proteases—From Basic Structure to Function to Drug Design as Targeted Therapy |
| title_full | Proteases—From Basic Structure to Function to Drug Design as Targeted Therapy |
| title_fullStr | Proteases—From Basic Structure to Function to Drug Design as Targeted Therapy |
| title_full_unstemmed | Proteases—From Basic Structure to Function to Drug Design as Targeted Therapy |
| title_short | Proteases—From Basic Structure to Function to Drug Design as Targeted Therapy |
| title_sort | proteases from basic structure to function to drug design as targeted therapy |
| topic | MMP MMP2 MMP9 MMP7 MMP14 matrix metalloproteases PDAC pancreatic cancer Bowman–Birk inhibitor ranacyclin trypsin inhibitor structure–activity relationship synergistic effect Gentamicin matrix metalloproteinase extracellular matrix nuclei cancer apoptosis immune response cysteine protease inhibitor stefin signal peptide parasite phylogenetic analysis diversification protein structure vascular endothelial growth factors (VEGFs) VEGF-A PlGF VEGF-B VEGF-C VEGF-D angiogenesis lymphangiogenesis CCBE1 proteases ADAMTS3 plasmin cathepsin D KLK3 prostate-specific antigen (PSA) thrombin wound healing metastasis proteolytic activation vascular biology lymphedema thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general |
| topic_facet | MMP MMP2 MMP9 MMP7 MMP14 matrix metalloproteases PDAC pancreatic cancer Bowman–Birk inhibitor ranacyclin trypsin inhibitor structure–activity relationship synergistic effect Gentamicin matrix metalloproteinase extracellular matrix nuclei cancer apoptosis immune response cysteine protease inhibitor stefin signal peptide parasite phylogenetic analysis diversification protein structure vascular endothelial growth factors (VEGFs) VEGF-A PlGF VEGF-B VEGF-C VEGF-D angiogenesis lymphangiogenesis CCBE1 proteases ADAMTS3 plasmin cathepsin D KLK3 prostate-specific antigen (PSA) thrombin wound healing metastasis proteolytic activation vascular biology lymphedema thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general |
| url | ONIX_20220111_9783036525754_928 |